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Abstract 
Background: There are increasing data suggesting the involvement of the immune 
system in narcolepsy. The co-occurrence of narcolepsy with other autoimmune 
disorders (including multiple sclerosis, MS) is rare.  
Patients and methods: International multicenter sleep center survey and literature 
review on narcolepsy with (NC) and without (NwC) cataplexy.  
Results: A total of 26 patients (pts), 6 in the survey and 20 in the literature were found. 
Two different type of association were identified: 1. Symptomatic type (5 pts): MS 
preceding the onset of narcolepsy, which was always without cataplexy (NwC); sleep 
onset REM episodes (SOREM) and hypocretin deficiency were observed in some, and 
lesions in the hypothalamus in all patients.  2. Coexisting type (18 pts): MS preceding or 
following the appearance of NC with SOREM, hypocretin deficiency but no lesions in 
the hypothalamus. A positive effect of steroids, immunoglobulins or natalizumab on 
narcolepsy symptoms was observed in 4 patients. 
Discussion: Narcolepsy and MS are rarely associated. In addition to NwC secondary to 
hypothalamic demyelination, some patients present a coexistence of MS with NC 
without detectable hypothalamic lesions. The rarity of reports on this association 
probably reflects underrecognition. The elucidation of underlying genetic and immune 
mechanisms needs further studies.   
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Introduction 
Narcolepsy with cataplexy (NC, narcolepsy type 1 (NT1)) is a chronic neurological 
disorder characterized by wake and sleep dysregulation (excessive daytime sleepiness 
(EDS), disturbed nocturnal sleep), and motoric (cataplexy, sleep paralysis, REM sleep 
behavior disorder), neuropsychiatric (hallucinations, depression) and metabolic/ 
endocrinological (obesity, precocious puberty) symptoms.  In some patients narcolepsy 
present without cataplexy (NwC); often cataplexy develops after a delay of years. 
Narcolepsy (NC and NwC) approximately affects 0.026-0.05% of the population in 
Europe and Northern America. Prevalence is found to be higher in Japan (0.59%) and 
lower in Israel (0.00023%). [1] Incidence rate is about 0.6-1/ 100.000 person-years.   
Based upon genetic, epidemiological and immunologic studies, narcolepsy is suggested 
to be an immune-mediated disorder. [2] NC is caused by the selective loss of hypocretin 
cells of the posterior hypothalamus that produce the neuropeptide hypocretin (HCRT). 
Correspondingly, cerebrospinal fluid (CSF) hypocretin-1 (hcrt-1) levels are 
low/undetectable in ∼90% of NC patients and in 20-30% of patients with NwC. [3] 
Patients today diagnosed as having narcolepsy with cataplexy probably have in some 
cases (those with HLA positivity and hypocretin deficiency) a similar 
etiopathophysiology as narcolepsy with cataplexy, in a significant number of cases its 
origine is however unclear.   
Immune dysfunction for narcolepsy with cataplexy is suspected on the basis of a strong 
association (>98% for NC) with human leukocyte antigen (HLA) DQB1*06:02, T-cell 
receptor (TCR) and P2RY11 polymorphisms, increased levels of Trib2-specific, and 
anti–streptolysin O antibody titers, and alterations in the cytokine profile. [2] 
Epidemiological and immunological observations indicate that different infections 
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(Streptococcus, H1N1) and vaccination with Pandemrix™ are potential triggering 
factors.  
Narcolepsy-like phenotypes are also described as paraneoplastic syndrome. In one of 
these cases, a CD8+ inflammatory-mediated response against hypocretin neurons was 
found. Special focus has been put on T-cell immune pathology in narcolepsy. 
Destruction of hypocretin producing neurons may be mediated by autoantigen specific 
CD4(+) T-cells or superantigen stimulated CD8(+) T-cells, or independent of T-cells by 
activation of DQB1*0602 signaling. [2,4]  
MS is a chronic inflammatory disease of the central nervous system (CNS) 
characterized by inflammation, demyelination, axonal injury and axonal loss. It is 
believed to be an autoimmune disorder, but the antigen specificity of the immune 
response is unknown. Autoreactive T cells activated outside the CNS cross the blood-
brain-barrier and are reactivated by local antigen-presenting cells. [4] Genetic 
susceptibility to MS is associated with the HLA region located on the short arm of 
chromosome 6 (6p21). Variations in this region can be positively or negatively 
associated with disease risk and disease course. The HLA class II region has the 
largest influence, with HLA-DRB1*1501 being the single strongest susceptibility locus, 
conferring a threefold increase in the MS risk. The frequency of the human leukocyte 
antigen DQB1*0602 was consistently found to be more prevalent (50-60% vs. 20-30%) 
in MS cases than in controls. [5,6] In MS, fatigue (>80%) is common, and EDS and 
sleep fragmentation are found in about 12-30% and 30-74%, respectively. [7] 
 
Aims 
The occurrence of narcolepsy and autoimmune disorders (including MS) is a 
controversial issue.  Anecdotally reports described the coexistence of narcolepsy with 
autoimmune disorders including multiple sclerosis. In a first systematic study, however, 
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no increased frequency of autoimmune disorders was found in patients with narcolepsy 
(with and without cataplexy) [8] and only one case was reported to have both 
narcolepsy and MS.  
We aimed at investigating frequency, characteristics and potential interactions of 
coexisting narcolepsy and MS a) in the literature and b) in a multi-center, international 
database survey.  
  
Patients and methods 
Retrospective sleep database multicenter survey in three large tertiary sleep centers 
with longstanding expertise in narcolepsy (Bern (CH), Leiden (NL), Witten/Hagen (DE)) 
for cases of coexisting narcolepsy and MS. This survey includes a population of approx. 
1200 narcolepsy patients. For diagnosis of narcolepsy, ICSD-3 criteria have been 
applied. The databases contain all patients diagnosed in the respective centers (during 
more than 15 years in Leiden and Bern, and during 8 years in Witten) and are regularly 
updated, also on comorbid disorders such as MS. 
 
For epidemiological data, a PubMed research was conducted for topical literature 
published until 30 June 2017. Search terms included narcolepsy, narcolepsy with and 
w/o cataplexy, cataplexy, NT1, NT2, hypocretin, orexin, multiple sleep latency test, 
Multiple Sclerosis, MS, encephalomyelitis disseminata, and disseminated sclerosis.  
In addition, review of published articles on comorbidities and/or coexisting autoimmune 
disorders of narcolepsy were used as primary resources.  
For grading and comparison, an estimation of co-existing cases of narcolepsy and MS 
has been calculated based upon available epidemiological data.  
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Ethics: The manuscript only includes data from a retrospective database analysis and 
literature search. Local ethical committees have approved the use of the database.   
 
 
Results 
Patients from survey of 3 narcolepsy centers 
We identified six patients with both narcolepsy and multiple sclerosis. All had cataplexy 
and were coexisting cases. 
For details please see Table 1. 
 
Patients from literature review 
Our research revealed 145 articles. After evaluation for content and relevance, 20 
patients (of whom 11 with cataplexy) could be identified. For details please see Table 2.  
 
Epidemiology:  
For comparability, prevalence data from Europe were selected. According United 
Nations (UN, 2015), Europe has 738 millions of habitants. European prevalence rates 
for narcolepsy (with cataplexy) and Multiple Sclerosis (all types) were used for 
calculation of overlapping cases (without projecting a potential causal or mechanistic 
association).  
For Europe calculated number of overlapping cases is between 77 and 1513 with a 
middle 50% range between 475 and 1115 people.  
For details see Table 3.  
Taken these numbers, the projected estimated number of cases is between 500 and 
8000 worldwide.  
 
Classification 
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After evaluation of all patients (new cases (n=6) and published cases (n=20)), we 
identified two different types of association between narcolepsy and multiple sclerosis. 
Articles in Table 2 are marked for types. Three out of 20 literature cases could not be 
classified due to lack of information.  
 
1. Symptomatic narcolepsy without cataplexy secondary to hypothalamic demyelination 
The two key features of this group are the presence of EDS as exclusive symptom of 
narcolepsy (n=5/5) and the occurrence of uni- or bilateral MS lesions in the 
hypothalamus (n=5/5). In no patient, cataplexy was reported whereas hypocretin levels 
were low/undetectable in 3 out of 5 pts. HLA-DQB1*0602 was positive in 0/2 pts. Sleep-
wake tests were available only in 2 patients: the first one had “SOREM periods” (no 
additional MSLT information available) and the second one had a normal mean sleep 
latency in MSLT and no SOREM periods. Oligoclonal bands, a typical finding in MS, 
were found in 1/1 patient. Narcolepsy appeared after the onset of MS (n=3/5, no data 
available in 2 patients). In one patient, steroid treatment (5 days, 500mg/d, 
intravenously) improved EDS for more than 18 months.  
 
2. Coexisting narcolepsy with cataplexy and relapsing remitting MS but without 
hypothalamic demyelination 
The key features of this group are the presence of narcolepsy with cataplexy and 
relapsing remitting (RR) MS in the absence of hypothalamic MS lesions. EDS was 
present in all patients (n=18), cataplexy in 17 of them. Sleep-wake tests were 
characteristic for narcolepsy in all patients tested (n=16/16). Low/undetectable CSF 
hypocretin levels were found in 6/6 patients. HLA haplotype status for DQB1*0602 (or 
DR2) was positive in 9 out of 9 patients and in 4/4 for HLA-DRB1*1501. In all patients 
clinical symptoms and course were typical for RRMS. MRI findings included the 
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absence of lesions in the hypothalamus (n=14/14) but the presence of different supra- 
and (rarely) infratentorial and spinal cord lesions. Oligoclonal bands,a typical finding in 
MS, were found in most patients (n=8/9). In 9/18 pts MS preceded, in 9 patients 
followed the onset of narcolepsy.  
Five patients were treated with disease modifying MS treatments: natalizumab (n=2), 
beta-interferons (n=2) and glatirameracetate (n=1). In one patient, ivig treatment, in one 
patient natalizumab therapy and in one patient, long-term steroid therapy resulted in an 
improvement of EDS. 
 
Discussion 
 Our series of coexisting narcolepsy and multiple sclerosis is the largest series 
published so far.  We identified two groups of patients. Secondary cases typically 
present with EDS and MS lesions in the hypothalamus but no cataplexy (NwC). 
Conversely, coexisting cases present with both EDS and cataplexy in the absence of 
hypothalamic lesions (but otherwise typical findings of RRMS).  
The reported cases with coexisting narcolepsy and MS are scarce (n=20, since 
1926). This contrasts with the results of our survey, showing a number within the 
calculated range for coexistence based on the prevalence of both disorders, This 
discrepancy with the cases published in the literature may be due to different reasons. 
Narcolepsy is an underdiagnosed disorder in general. In addition, narcolepsy in MS is 
probably also underdiagnosed because fatigue, tiredness, muscle weakness and 
disturbed nocturnal sleep are frequent in MS. 
Although epidemiologic considerations alone do not allow pathophysiologic 
considerations we suggest that, based upon additional indirect evidence (see below), a 
link between narcolepsy and MS could exist.  
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The observation of secondary narcolepsy in the context of hypothalamic damage 
is not surprising. [9] It is of interest, however, that only rarely, demyelinating disease 
involving the hypothalamus was reported to give rise to narcolepsy, typically without 
cataplexy. In fact, we did not find as single case of narcolepsy with cataplexy with a 
defined hypothalamic lesion due to MS. Noteworthy, NC was described in few patients 
with neuromyelitis optica (NMO) and involvement of the hypothalamus. [10] 
The possibility of a co-occurrence of both disorders through possibly shared underlying 
immunological mechanisms should be discussed. This could result from genetic factors 
(e.g. HLA DQB1*0602 and DRB1*1501), the environment or an interaction of the two. 
Ekbom reported the exceptional association of familial MS and NC in a single family. 
[11] The rarity of this association despite the presence of similar HLA predisposition 
may be due to differences in (other) predisposing and protective genes. In study of 18 
MS patients no association was found between HLA DQB1*0602 positivity (found in 6 of 
them) and narcolepsy like features. However, two out of 6 HLA patients also carried a 
protective gene (DQB1*02). [12] The need of other factors besides 
DRB1*15:01/DQB1*06:02 to develop either one of the two disorders is underlined by 
the report of monozygotic twins, one of which developed narcolepsy with cataplexy 
whereas the other one presented with the other multiple sclerosis. [13] In narcolepsy 
HLA-DRB1*03- DQB1*02 and HLA-DQB1*0603 were reported to be protective. [14] 
However, in MS HLA-DRB1*03:01 is one of the risk alleles [15] and HLA DQB1*0602 as 
well as DQB1*0603 are associated with more severe damage on inflammatory and 
neurodegenerative MRI measures in MS. [16] Hence, risk genes for MS (or narcolepsy) 
might have a protective function for narcolepsy (or MS) either by being protective 
themselves or by allele competition. [17] In fact, other protective mechanisms besides 
the genetically determined HLA predisposition are probably necessary and include 
specific immune pathways and reactions (possibly T cell mediated) that arise in MS and 
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influence the vulnerability to develop narcolepsy with cataplexy (or vice versa). In a 
study profiling the autoantibody repertoire in plasma/serum MS and NC samples using 
high-density peptide microarrays, different reactivity patterns between and among the 
narcolepsy and MS-related sample groups were found. [18]  Myelin oligodendrocyte 
glycoprotein (MOG) has been suggested to have a central role in the regulation of 
tolerance and autoimmunity. MOG antibodies have been described in patients 
presenting with acute demyelinating disease of the central nervous system, often 
previously labeled under MS syndrome. [19] Interestingly, a MOG missense mutation 
has been identified as cause of familial narcolepsy with cataplexy. [20] In a recent study 
(Latorre D et al., submitted), we could provide additional evidence for the autoimmune 
pathogenesis of narcolepsy. We used combined antigenic stimulation, T cell cloning, 
and TCR sequencing in order to interrogate memory T cells from narcolepsy patients 
and found autoreactive CD4+ T cells specific for HCRT in 18/19 patients, but only rarely 
in healthy donors. Memory CD8+ T cells specific for HCRT and memory CD4+ T cells 
specific for TRIB2, a self-antigen expressed by hypocretin-producing neurons, were 
also found in some patients. Highest frequency of HCRT-reactive T cells were found in 
a patient with coexisting NC and MS. Our results establish that CD4+ / CD8+ T cell 
reactivity to self-antigens expressed by HCRT-producing neurons is associated with 
narcolepsy. [21]  
 The impact of intravenous immunoglobulin (ivig) and natalizumab therapy on 
EDS in two of our patients is interesting and may point to some effect of 
immunomodulatory treatments in single/selected patients with narcolepsy. In line with 
this, an improvement of fatigue and also EDS in MS patients by natalizumab treatment 
was recently shown. [22, 23]  
Our study points to the possibility of a direct/causative link between narcolepsy 
and MS and by this further supports the hypothesis of an autoimmune pathophysiology 
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of narcolepsy. More research is needed to elucidate the nature of this link (including the 
possible existence of mechanisms predisposing and/or protecting for both diseases) 
and the potential implications for future (immunomodulatory?) treatments of narcolepsy.  
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